S17 Ep24: Evolving ESR1 Mutation Testing Directions Complicate the Future of Metastatic Breast Cancer Management: With Pedram Razavi, MD, PhD; and Dara S. Ross, MD
About this episode
The episode discusses the evolution of ESR1 mutation testing and its implications for metastatic breast cancer management with experts from Memorial Sloan Kettering Cancer Center.
In today’s episode, we welcomed Pedram Razavi, MD, PhD, and Dara S. Ross, MD. Dr Razavi is a breast medical oncologist and director of Liquid Biopsy & Genomics at Memorial Sloan Kettering Cancer Center in New York, New York. Dr Ross is an associate attending pathologist at Memorial Sloan Kettering Cancer Center. In our exclusive interview, Drs Razavi and Ross discussed the evolution of ESR1 mutation–directed breast cancer management, emphasizing the role of comprehensive genomic testing at metastatic recurrence, including liquid biopsy and tissue sequencing. They highlighted that ESR1 mutations can develop in patients receiving aromatase inhibitors and that the detection of these mutations is crucial for treatment decisions. They also highlighted findings from the phase 3 SERENA-6 trial (NCT04964934), which tested switching to camizestrant upon the emergence of an ESR1 mutation during treatment with an aromatase inhibitor and a CDK4/6 inhibitor ahead of radiographic disease progression in patients with hormone receptor–positive, HER2-negative metastatic breast cancer. Despite concerns from the FDA's Oncologic Drugs Advisory Committee (ODAC) about SERENA-6’s design and overall…
More episodes of OncLive® On Air
- S17 Ep29: Navigating Radiation, Systemic Therapy, and Multidisciplinary Care in Skin Cancer: With Hirsch Matani, MD; Elizabeth Zhang-Velten, MD, PhD; and Binh T. Ngo, MD
- S17 Ep28: In-House Molecular Testing in NSCLC Improves Turnaround Time, Tissue Stewardship, and Multidisciplinary Coordination: Featuring Anthony Chi, MD; Monica Peravali, MD; and Archana Jadhav, MD
- S17 Ep27: Advances in Cervical Cancer: Prevention, Immunotherapy, and the Rise of Antibody-Drug Conjugates: With Ursula A. Matulonis, MD; and Meghan E. Shea, MD
- S17 Ep26: Emerging Targets, Second-Line Standards, and Molecular Subtyping Signal a New Era in SCLC Care: With Jacob Sands, MD
- S17 Ep25: TKIs Continue to Move Forward and Expand Their Potential in CML: With Michael J. Mauro, MD
- S17 Ep22: Answering Key Clinical Questions About Esophageal Cancer Care: With Peter Enzinger, MD
Explore listener stats, chart rankings, contacts and more on the OncLive® On Air podcast page.